everolimus + cyclosporine + Prednison (continuous steroids)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
de Novo Kidney Transplant Recipients
Conditions
de Novo Kidney Transplant Recipients, Renal Transplantation
Trial Timeline
Apr 1, 2009 → Jul 1, 2012
NCT ID
NCT01023815About everolimus + cyclosporine + Prednison (continuous steroids)
everolimus + cyclosporine + Prednison (continuous steroids) is a phase 3 stage product being developed by Novartis for de Novo Kidney Transplant Recipients. The current trial status is completed. This product is registered under clinical trial identifier NCT01023815. Target conditions include de Novo Kidney Transplant Recipients, Renal Transplantation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01023815 | Phase 3 | Completed |
Competing Products
19 competing products in de Novo Kidney Transplant Recipients